Genetics Home Reference: familial acute leukemia with mutant CEBPA

Familial acute leukemia with mutant CEBPA, is one form of cancer of blood-forming tissue (bone marrow) called acute leukemia. In normal bone marrow, early blood cells called necrosis stem cells turn into several types of blood cells: white blood cells (leukocytes), which protect the body from infection, red blood cells (erythrocytes) that have oxygen and blood platelets (points), which are involved in the clotting of blood. Acute leukemia bone marrow produces a large number of abnormal white blood cells, immature, blasts called szpikowa. Instead of developing to a normal white blood cells, szpikowa blasts develop into bronchial cells leukemia. A large number of abnormal cells in the bone marrow interferes with the production of white blood cells, functional red blood cells and blood platelets.

People with familial acute leukemia with CEBPA mutated to a shortage of white blood cells (leukopenia), leading to increased susceptibility to infections. A low number of red blood cells (anemia) also occurs in this disorder, causing fatigue and weakness. People affected by the disease are also reducing the amount of blood platelets (Thrombocytopenia), which may result in easy bruising and irregular bleeding. Other symptoms of familial acute leukemia with mutant CEBPA may include the loss of the horse and weight.

Acute leukemia in General is a disease of older people, familial acute leukemia with mutant CEBPA often starts earlier in life and has been reported to occur already at the age of 4. Between 50 and 65 per cent of the persons affected to survive their disease, compared to 25 to 40 per cent of these other forms of acute leukemia. However, people with familial acute leukemia with CEBPA mutant have higher risk of a new instance of the core is the disorder after successful treatment of the initial instance.

These resources Address the diagnosis or management of familial acute leukemia with mutant CEBPA, and may include treatment of suppliers.

You can also learn about the diagnosis or management of familial acute leukemia with mutant CEBPA educational resources and support to patients.

To locate a provider of health care, see how do I find a genetics professional in my area? in the manual.

The following resources about familial acute leukemia with CEBPA mutant may find useful. These materials are written for the general public.

Can also be interested in these resources, which are intended for health professionals and researchers.

The manual contains basic information about genetics in clear language.

These links provide additional resources of modern genetics, which may be useful.

The resources on this page should not be used as a substitute for professional medical care or advice. Users seeking personal information of genetic disease, syndrome or condition, consult with a qualified professional care. See how you can find a genetics professional in my area? in the manual.

View the original article here

This post was made using the Auto Blogging Software from WebMagnates.org This line will not appear when posts are made after activating the software to full version.

Genetics Home Reference: dystonia l-dopa unresponsive

L-dopa unresponsive dystonia is a disorder that involves involuntary contractions of muscles, tremors, and other uncontrolled movements (dystonia). Features of this condition range from mild to severe. This form of dystonia is called l-dopa responsive dystonia, since the signs and symptoms usually increase sustainable use of drugs known as l-dopa.

The signs and symptoms of l-dopa unresponsive dystonia usually appear during childhood, usually around the age of 6. The first signs of the State are usually the development-and upwards-return rates (clubfeet) and dystonia in amputation. Dystonia spreads on hand at the time; beginning in adolescence, the whole body is usually involved. People affected by the disease may have abnormal limb positioning and lack of coordination during walking or running. Some people with this condition have problems with sleep or episodes of depression more often than normally expected.

Over time, the people affected by the disease often develop group is the irregularity of movement called Parkinsonism. These abnormalities include unusually slow movement (bradykinesia), rigidity, tremors and inability to hold the body upright and balanced (postural instability).

Movement difficulties related to l-dopa unresponsive dystonia usually worsen with age, but to stabilize around the age of 30. Characteristic feature of l-dopa unresponsive dystonia is worsening the problems flow later in the day and the improvement of symptoms in the morning after sleep (diurnal fluctuations).

Rarely flow problems related to l-dopa unresponsive dystonia do not appear until adulthood. In such cases of adult onset Parkinsonism usually develops before the dystonia, and movement problems are slowly increasing, and do not Show diurnal fluctuations.

L-dopa unresponsive dystonia is estimated at 1 million people around the world. However, the disorder is likely under diagnosed because the condition may not be identified in people with mild symptoms, or may be Misdiagnosed in people who are similar to other treat disorders symptoms.

A mutation of the gene GCH1 is the most common cause of dystonia l-dopa unresponsive. Rarely a mutation of the gene TH or SPR cause this condition.

Gen GCH1 instructions for making the enzyme called GTP cyclohydrolase. The enzyme is involved in the first of the three stages of production of a molecule called tetrahydrobiopterin (BH4). Gene SPR instructions for making the enzyme sepiapterin reductase, is engaged in the last stage of the production of tetrahydrobiopterin. Tetrahydrobiopterin helps you process several protein building blocks (amino acids) and is involved in the production of chemical substances called neurotransmitters that transmit signals between neurons in the brain. In particular, tetrahydrobiopterin is engaged in the production of two neurotransmitters called dopamine and serotoniny. Among the many functions of dopamine transmits signals in the brain to produce smooth physical movements and serotoniny regulates mood, emotion, sleep and appetite.

The protein produced from the gene TH. is also involved in the production of dopamine. The gene for tryptophan hydroxylase enzyme TH instructions, which helps you convert the amino acid tyrosine dopamine.

A mutation of the gene GCH1, or SPR interfere with production of tetrahydrobiopterin, which leads to a reduction in the amount of dopamine available. In the production of the enzyme tyrosine hydroxylase function reduced, leading to a reduction in the production of dopamine by TH mutation. Reduction in the amount of dopamine to interfere with the ability of the brain to produce smooth physical movements, dystonia, tremor and other problems flow associated with dystonia l-dopa unresponsive. Disorders of sleep and mood also occur in some people with GCH1 or SPR gene mutations; such disorders may result from interference in the production of serotoniny. Problems with sleep and episodes of depression are not visible in people with l-dopa unresponsive dystonia due to TH mutation, which is sometimes referred to as the band Segawa.

Some people with l-dopa unresponsive dystonia has identified mutations in the GCH1, cz, or SPR gene. Status reason in these people is unknown.

Learn more about genes GCH1, SPR and GREN.

When l-dopa unresponsive dystonia is caused by a mutation of the gene GCH1, is inherited autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to disorder. In some cases, the affected person inherits a mutation affected parent. Other cases arising from new mutations in the gene and occur in people history of the disorder in their family.

Some people who will inherit the changed gene GCH1 never expands features of dystonia l-dopa unresponsive. (This situation is known as a reduced penetrance). It is not clear Why some people with the mutated gene is the development of the disease, not the other people of the mutated gene. For unknown reasons correspond to l-dopa dystonia due to mutation of the gene GCH1 concerns females two to four times more often than males.

When TH mutations are responsible for causing l-dopa unresponsive dystonia, is inherited autosomal recessive pattern, which means both copies of the gene in each cell mutation. Autosomal recessive condition of the parents who each carry one copy of the mutated gene, but usually do not show signs and symptoms of the condition.

When l-dopa unresponsive dystonia is caused by a mutation of the gene SPR, may have autosomal recessive or, more rarely, autosomal dominant pattern of inheritance.

These resources Address the diagnosis or management of l-dopa unresponsive dystonia and may include treatment of suppliers.

You can also learn about the diagnosis or management of l-dopa unresponsive dystonia educational resources and support to patients.

To locate a provider of health care, see how do I find a genetics professional in my area? in the manual.

The following resources with l-dopa unresponsive dystonia may find useful. These materials are written for the general public.

Can also be interested in these resources, which are intended for health professionals and researchers.

Dystonia progressive with diurnal fluctuations marked DRDhereditary

For more information about names, see genetics Genetics Home Reference condition names guidelines and how genetic conditions and genes called? in the manual.

The manual contains basic information about genetics in clear language.

These links provide additional resources of modern genetics, which may be useful.

The resources on this page should not be used as a substitute for professional medical care or advice. Users seeking personal information of genetic disease, syndrome or condition, consult with a qualified professional care. See how you can find a genetics professional in my area? in the manual.

View the original article here

This post was made using the Auto Blogging Software from WebMagnates.org This line will not appear when posts are made after activating the software to full version.

The National Library of Medicine releases free iPad App, "Native Voices: the Native peoples ' concepts of health and disease"

To give those who cannot travel to Bethesda, Maryland to see him personally lively experience of virtual, National Library Medicine (NLM) announces new iPad app, free, which captures the contents of its popular exhibitions, Native Voices: the native inhabitants of the concepts of health and disease (http://www.nlm.nih.gov/nativevoices/index.html), currently on display. NLM is the world's largest medical library and component of the National Institutes of Health.

The application allows users to explore video chat with members of the tribal elders, tribal healers and other prominent people practice traditional medicine, Western medicine, or a combination of both. Experience the unique and the prospects they weave tapestry vibrant and diverse cultures and ways of medicine practiced by the Natives of Alaska, native Americans and native Hawaiians. Other clips video provides an overview of the exhibition and the stresses of travel 4,400-mile had ordered a totem of specially crafted for exhibition from Washington State to the NIH campus in Bethesda, Maryland.

App NLM Native Voices works on all iPads with iOS 4.2 and higher. To download the free app, go to the Apple iTunes store (www.apple.com/iTunes) and type in "NLM Native Voices."

In addition to the content of the native Voices: the native inhabitants of the concepts of health and disease, the application contains a function "of the NLM", which allows the public to obtain information on the National Library of Medicine, and also learn how to "visit the NLM" and "Connect with NLM" through social media outlets.

On the welcome page of the app NLM Native Voices shows the logo of the exhibition and of the four featured interview subjects.

NLM Director Dr. Donald A.B. Lindberg (left top) provides an overview of the Native Voices: the native inhabitants of the concepts of health and disease, this exhibition home users and applications, you can also examine the rich content on five main topics: individual, Community, tradition, healing and nature.

Interviews on app NLM Native Voices can be searched by key words, respondent name or, as shown here, the topic. The speakers presented to talk about the importance of taking responsibility for their own health and the health of their Communities.

View the original article here

This post was made using the Auto Blogging Software from WebMagnates.org This line will not appear when posts are made after activating the software to full version.

Timing is Everything with Breast Cancer

Click Here!

Good Laboratory Practices for Biochemical Genetic Testing and Newborn Screening for Inherited Metabolic Disorders
CE Available
This report provides recommendations for good laboratory practices for biochemical genetic testing and newborn screening for inherited metabolic disorders. The recommended practices address the benefits of using a quality management system approach, factors to consider before introducing new tests, establishment and verification of test performance specifications, the total laboratory testing process, confidentiality of patient information and test results, and personnel qualifications and responsibilities for laboratory testing for inherited metabolic diseases. These recommendations are intended for laboratories that perform biochemical genetic testing to improve the quality of laboratory services and for newborn screening laboratories to ensure the quality of laboratory practices for inherited metabolic disorders. These recommendations also are intended as a resource for medical and public health professionals who evaluate laboratory practices, for users of laboratory services to facilitate their collaboration with newborn screening systems and use of biochemical genetic tests, and for standard-setting organizations and professional societies in developing future laboratory quality standards and practice recommendations.

Watch Your Head

Good Laboratory Practices for Biochemical Genetic Testing and Newborn Screening for Inherited Metabolic Disorders
CE Available Click Here!
This report provides recommendations for good laboratory practices for biochemical genetic testing and newborn screening for inherited metabolic disorders. The recommended practices address the benefits of using a quality management system approach, factors to consider before introducing new tests, establishment and verification of test performance specifications, the total laboratory testing process, confidentiality of patient information and test results, and personnel qualifications and responsibilities for laboratory testing for inherited metabolic diseases. These recommendations are intended for laboratories that perform biochemical genetic testing to improve the quality of laboratory services and for newborn screening laboratories to ensure the quality of laboratory practices for inherited metabolic disorders. These recommendations also are intended as a resource for medical and public health professionals who evaluate laboratory practices, for users of laboratory services to facilitate their collaboration with newborn screening systems and use of biochemical genetic tests, and for standard-setting organizations and professional societies in developing future laboratory quality standards and practice recommendations.

You Can Quit Smoking

Good Laboratory Practices for Biochemical Genetic Testing and Newborn Screening for Inherited Metabolic Disorders
CE Available

Click Here!

This report provides recommendations for good laboratory practices for biochemical genetic testing and newborn screening for inherited metabolic disorders. The recommended practices address the benefits of using a quality management system approach, factors to consider before introducing new tests, establishment and verification of test performance specifications, the total laboratory testing process, confidentiality of patient information and test results, and personnel qualifications and responsibilities for laboratory testing for inherited metabolic diseases. These recommendations are intended for laboratories that perform biochemical genetic testing to improve the quality of laboratory services and for newborn screening laboratories to ensure the quality of laboratory practices for inherited metabolic disorders. These recommendations also are intended as a resource for medical and public health professionals who evaluate laboratory practices, for users of laboratory services to facilitate their collaboration with newborn screening systems and use of biochemical genetic tests, and for standard-setting organizations and professional societies in developing future laboratory quality standards and practice recommendations.

Restless legs syndrome and conditions associated with metabolic dysregulation, sympathoadrenal dysfunction, and cardiovascular disease risk: A systematic review

Kim E. Innesa, b, , , Terry Kit Selfea, b, c, , Parul Agarwala, d, a Department of Community Medicine, West Virginia University School of Medicine, PO Box 9190, Morgantown, WV 26506-9190, USAb Center for the Study of Complementary and Alternative Therapies, University of Virginia Health System, PO Box 800782, McLeod Hall, Charlottesville, VA 22908-0782, USAReceived 1 February 2011. Revised 7 April 2011. Accepted 11 April 2011. Available online 5 July 2011.View full text Restless legs syndrome (RLS) is a distressing sleep and sensorimotor disorder that affects a large percentage of adults in the western industrialized world and is associated with profound reductions in quality of life. However, the etiology of RLS remains incompletely understood. Enhanced understanding regarding both the antecedents and sequelae of RLS could shed new light on the pathogenesis of RLS. Evidence from an emerging body of literature suggests associations between RLS and diabetes, hypertension, obesity, and related conditions linked to sympathetic activation and metabolic dysregulation, raising the possibility that these factors may likewise play a significant role in the development and progression of RLS, and could help explain the recently documented associations between RLS and subsequent cardiovascular disease. However, the relation between RLS and these chronic conditions has received relatively little attention to date, although potential implications for the pathogenesis and treatment of RLS could be considerable. In this paper, we systematically review the recently published literature regarding the association of RLS to cardiovascular disease and related risk factors characterized by sympathoadrenal and metabolic dysregulation, discuss potential underlying mechanisms, and outline some possible directions for future research.

prs.rt("abs_end");Restless legs syndrome; RLS; Ekbom disease; Cardiovascular disease; Hypertension; Diabetes; Impaired glucose tolerance; Obesity; Weight gain; Dyslipidemia; Autonomic dysfunction; HPA axis dysfunction

Figures and tables from this article:

Table 1. Summary table of study characteristics. N = 30 studies (1995-2010).

Abbreviations: CVD = cardiovascular disease; DM = diabetes; DM2 = type 2 diabetes; dx = diagnosis; IGT = impaired glucose tolerance: IRLSSG = international restless legs syndrome study group; Min freq/sev = minimum frequency and/or severity; pts = patients; pts = patients; VA = veterans administration; w/ = with.

View Within ArticleTable 2. Relation of RLS to cardiovascular disease. Summary of study characteristics and findings (N = 15 studies published between 1995 and 2010).

Abbreviations: appt = appointment; ARIC = atherosclerosis risk in communities; BOLD = the burden of obstructive lung diseases study; BP = blood pressure; btwn = between; CAD = Coronary artery disease; CHF = congestive heart failure; CHS = cardiovascular health study; condn = condition; CVD = cardiovascular disease; DM = diabetes mellitus; DM2 = type 2 diabetes; dx = diagnosis; ECA = epidemiologic catchment area; F=female; FBG = fasting blood glucose; FHS = framingham heart study; Freq = frequency; Hgb = hemoglobin; HPFS = health professionals follow-up study; HTN = hypertension; hx = history; ICD = International Classification of Diseases; ICSD = international classification of sleep disorders; IRLS = international RLS study group rating scale; IRLSSG = international restless legs syndrome study group; M = male; MEMO = the memory and morbidity in augsburg elderly study; MI = myocardial infraction; MONICA = monitoring trends and determinants in CVD survey-Augsburg; n’s = numbers; NC-FP-RN = north carolina family practice research network; NHS II = nurses health study II; NSF = national sleep foundation poll; NY cohorts = new york hypertension cohorts; OR = odds ratio (95% Confidence Interval); pt = patient; RLS = restless legs syndrome; SDB = sleep disordered breathing; SHHS = sleep heart health study; SHS = strong heart study; SPAR = the official database covering the total population of Sweden; Sx = symptoms; TG = triglycerides; Tucson cohorts = tucson epidemiologic study of airways obstructive diseases and the health and environment study; tx = treatment; VA = veterans administration; w/ = with; w/o = without.*Calculated from data provided in paper.

View Within ArticleTable 3. Relation of RLS to hypertension: Summary of study characteristics and findings (N = 17 studies published between 1995 and 2010).

Abbreviations: appt = appointment; ARIC = atherosclerosis risk in communities; BOLD = the burden of obstructive lung diseases study; BP = blood pressure; btwn = between; CHF = congestive heart failure; CHS = cardiovascular health study; condn = condition; CVD = cardiovascular disease; DBP = diastolic blood pressure; DM = diabetes mellitus; DM2 = type 2 diabetes; DM1 = type 1 diabetes; dx = diagnosis; ECA = epidemiologic catchment area; F=female; FBG = fasting blood glucose; FHS = framingham heart study; Freq = frequency; Hgb = hemoglobin; HPFS = health professionals follow-up study; HTN = hypertension; hx = history; ICD9CM = international classification of diseases, 9th revision, clinical modification; ICSD = international classification of sleep disorders; IRLS = international RLS study group rating scale; IRLSSG = international restless legs syndrome study group; M = male; MEMO = the memory and morbidity in augsburg elderly study; MI = myocardial infarction; MONICA = monitoring trends and determinants in CVD survey-Augsburg; n’s = numbers; NC-FP-RN = north carolina family practice research network; NHS II = nurses health study II; NSF = national sleep foundation poll; NY cohorts = new york hypertension cohorts; OR = odds ratio (95% Confidence Interval); Pt = patient; RLS = restless legs syndrome; SBP = systolic blood pressure; SDB = Sleep disordered breathing; SHHS = sleep heart health study; SHS = strong heart study; SPAR = the official database covering the total population of Sweden; Sx = symptoms; TG = triglycerides; Tucson cohorts = tucson epidemiologic study of airways obstructive diseases and the health and environment study; tx = treatment; VA = veterans administration; w/ = with; w/in = within; w/o = without.* Calculated from data provided in paper.

View Within ArticleTable 4. Relation of RLS to diabetes and impaired glucose tolerance: Summary of study characteristics and findings (N=26 studies (1995-2010)).

Abbreviations: appt = appointment; ARIC = atherosclerosis risk in communities; BG = blood glucose; BMI = body mass index; BOLD = the burden of obstructive lung diseases study; BP = blood pressure; btwn = between; CHF = congestive heart failure; CHS = cardiovascular health study; condn = condition; CVD = cardiovascular disease; DM = diabetes mellitus; DM1 = type 1 diabetes; DM2 = type 2 diabetes; dx = diagnosis; ECA = epidemiologic catchment area; F=female; FBG = fasting blood glucose; FHS = framingham heart study; Freq = frequency; Hgb = hemoglobin; HOMA = homeostasis model assessment; HPFS = health professionals follow-up study; HTN = hypertension; hx = history; ICD9CM = international classification of diseases, 9th revision, clinical modification; IGT = impaired glucose tolerance; ICSD = international classification of sleep disorders; IGR = impaired glucose regulation; IGT = impaired glucose tolerance; IRLS = international RLS study group rating scale; IRLSSG = international restless legs syndrome study group; M = male; MEMO = the memory and morbidity in augsburg elderly study; MONICA = monitoring trends and determinants in CVD survey-Augsburg; NC-FP-RN = north carolina family practice research network; NHS II = nurses health study II; NSF = national sleep foundation poll; NY cohorts = new york hypertension cohorts; OGTT = oral glucose tolerance test; OR = odds ratio (95% Confidence Interval); pts = patients; RLS = restless legs syndrome; SDB = sleep disordered breathing; SHHS = sleep heart health study; SHS = Strong heart study; SPAR = the official database covering the total population of Sweden; Sx = symptoms; TG = triglycerides; Tucson cohorts = tucson epidemiologic study of airways obstructive diseases and the health and environment study; tx = treatment; VA = veterans administration; w/ = with; w/in = within; w/o = without.*Calculated from data provided in table.

View Within ArticleTable 5. Relation of RLS to obesity, weight gain, and dyslipidemia: Summary of study characteristics and findings (N=18 studies with data on the association of RLS to obesity/weight gain, 7 studies with data on the association of RLS to lipid profiles).

Abbreviations: appt = appointment; ARIC = atherosclerosis risk in communities; BMI = body mass index; BOLD = the burden of obstructive lung diseases study; BP = blood pressure; btwn = between; CHF = congestive heart failure; CHS = cardiovascular health study; condn = condition; CVD = cardiovascular disease; DM = diabetes mellitus; DM1 = type 1 diabetes; DM2 = type 2 diabetes; dx = diagnosis; ECA = epidemiologic catchment area; F=female; FBG = fasting blood glucose; FHS = framingham heart study; Freq = frequency; Hgb = hemoglobin; HPFS = health professionals follow-up study; HTN = hypertension; hx = history; ICSD = international classification of sleep disorders; IRLS = intl RLS study group rating scale; IRLSSG = international restless legs syndrome study group; M = male; MEMO = the memory and morbidity in augsburg elderly study; MI = myocardial infarction; MONICA = Monitoring trends and determinants in CVD survey-Augsburg; NC-FP-RN = north carolina family practice research network; NHS II = nurses health study II; NSF = national sleep foundation poll; NY cohorts = new york hypertension cohorts; OGTT = oral glucose tolerance test; OR = odds ratio (95% confidence interval); RLS = restless legs syndrome; SDB = sleep disordered breathing; SHHS = sleep heart health study; SHS = strong heart study; SPAR = the official database covering the total population of Sweden; Sx = symptoms; TG = triglycerides; Tucson cohorts = tucson epidemiologic study of airways obstructive diseases and the health and environment study; tx = treatment; VA = veterans administration; w/ = with; w/o = without.*Calculated from data provided in paper.

View Within ArticleCopyright © 2011 Elsevier Ltd. All rights reserved.

prs.rt('data_end');

View the original article here